Skip to main content
. 2017 Sep 25;10(3):185–191. doi: 10.3400/avd.oa.17-00059

Table 2 Incremental cost-effectiveness ratio of EVAR for patients operated on for pancreas cancer.

AAA size Stage of pancreas cancer
I II III IVa IVb
Median LY* 6.34 3.60 2.56 1.08 0.59
Expected LY* 6.34 5.40 3.07 2.06 1.61
ICER# 5.0–5.9 cm 3.59 4.48 24.00 127.10 198.43
6.0–6.9 cm 2.14 2.43 8.73 25.68 47.13
≧7 cm 1.20 1.34 4.11 8.98 14.19

*life years, #incremental cost-effectiveness ratio (million yen/QALY)